ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Forest Laboratories will shell out $2.9 billion in cash to acquire privately held specialty pharmaceuticals firm Aptalis. The deal for Aptalis, which had sales of $688 million in fiscal 2013, diversifies Forest’s product portfolio into gastrointestinal and cystic fibrosis treatments. Forest, which recently unveiled plans to cut 9% of its workforce as it struggles with generics competition for its antidepressant Lexapro, believes it can achieve $125 million in cost synergies between the two companies. The deal is expected to close in the first half of this year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X